Author:
Solymosi Tamás,Ötvös Zsolt,Angi Réka,Ordasi Betti,Jordán Tamás,Semsey Sándor,Molnár László,Ránky Soma,Filipcsei Genovéva,Heltovics Gábor,Glavinas Hristos
Funder
Aurigon-Toxicoop Research Center Ltd
Reference23 articles.
1. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men;Acharya;Cancer Chemother. Pharmacol.,2012
2. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability;Amidon;Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci.,1995
3. Novel continuous flow technology for the development of a nanostructured Aprepitant formulation with improved pharmacokinetic properties;Angi;Eur. J. Pharm. Biopharm.,2014
4. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven;Attard;J. Clin. Oncol.,2008
5. PAMPA – A drug absorption in vitro model: 11. Matching the in vivo unstirred water layer thickness by individual-well stirring in microtitre plates;Avdeef;Eur. J. Pharm. Sci.,2004
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献